Medications for Alzheimer disease: Nursing pharmacology

Last updated: March 09, 2026

Medications for Alzheimer disease: Nursing pharmacology

FINAL EXAM PHARM

FINAL EXAM PHARM

Antihistamines: Nursing pharmacology
Bronchodilators: Nursing pharmacology
Respiratory stimulants: Nursing pharmacology
Antidepressants - SSRIs and SNRIs: Nursing pharmacology
Antidepressants - Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs): Nursing pharmacology
Antipsychotics: Nursing pharmacology
Anxiolytics and sedative-hypnotics: Nursing pharmacology
Stimulant medications for attention-deficit hyperactivity disorder (ADHD): Nursing pharmacology
Mood stabilizers: Nursing pharmacology
Medications affecting the parathyroid glands: Nursing pharmacology
Medications for antidiuretic hormone (ADH) disorders: Nursing pharmacology
Medications for thyroid disorders: Nursing pharmacology
Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics: Nursing pharmacology
Oral antidiabetic medications - Alpha-glucosidase inhibitors: Nursing pharmacology
Oral antidiabetic medications - Biguanides and thiazolidinediones: Nursing pharmacology
Oral antidiabetic medications - DPP-4 inhibitors: Nursing pharmacology
Oral antidiabetic medications - Sulfonylureas and meglitinides: Nursing pharmacology
Oral antidiabetic medications - Sodium-glucose co-transporter-2 (SGLT-2) inhibitors: Nursing pharmacology
Medications for growth hormone disorders: Nursing pharmacology
Insulin: Nursing pharmacology
Glucocorticoids and mineralocorticoids: Nursing pharmacology
Antiglaucoma medications: Nursing pharmacology
Eye anesthetics: Nursing pharmacology
Mydriatics and cycloplegics: Nursing pharmacology
Ophthalmic anti-inflammatories and anti-infectives: Nursing pharmacology
Angiotensin II receptor blockers (ARBs): Nursing pharmacology
Angiotensin-converting enzyme (ACE) inhibitors: Nursing pharmacology
Antiarrhythmics: Nursing pharmacology
Beta-adrenergic blockers: Nursing pharmacology
Calcium-channel blockers: Nursing pharmacology
Cardiac glycosides: Nursing pharmacology
Direct-acting vasodilators: Nursing pharmacology
Nitrates: Nursing pharmacology
Alpha-1 adrenergic blockers: Nursing pharmacology
Alpha-2 adrenergic agonists: Nursing pharmacology
Antacids: Nursing pharmacology
Antidiarrheals: Nursing pharmacology
Antiemetics: Nursing pharmacology
Gallstone-dissolving agents: Nursing pharmacology
Gastric mucosal protective agents: Nursing pharmacology
Antispasmodics (GI): Nursing pharmacology
Histamine H2 antagonists: Nursing pharmacology
Proton pump inhibitors (PPIs): Nursing pharmacology
Treatment for Helicobacter pylori: Nursing pharmacology
Laxatives: Nursing pharmacology
Weight loss medications: Nursing pharmacology
Medications for hepatic encephalopathy: Nursing pharmacology
Anticoagulants - Heparin: Nursing pharmacology
Anticoagulants - Warfarin: Nursing pharmacology
Antihyperlipidemics - Statins: Nursing pharmacology
Antiplatelet agents: Nursing pharmacology
Hemostatics: Nursing pharmacology
Iron preparations: Nursing pharmacology
Thrombolytics: Nursing pharmacology
Antihyperlipidemics - Fibrates: Nursing pharmacology
Blood products: Nursing pharmacology
Antihyperlipidemics - Bile acid sequestrants and cholesterol absorption inhibitors: Nursing pharmacology
Anticoagulants - Direct thrombin and factor Xa inhibitors: Nursing pharmacology
Antihyperlipidemics - Miscellaneous: Nursing pharmacology
Hematopoietic growth factors: Nursing pharmacology
Biologic agents: Nursing pharmacology
Non-biologic disease-modifying antirheumatic drug (DMARD) therapy: Nursing pharmacology
Vaccines: Nursing pharmacology
Immunoglobulins: Nursing pharmacology
Immunosuppressants for autoimmune diseases: Nursing pharmacology
Immunomodulators: Nursing pharmacology
Disease-modifying therapy for multiple sclerosis: Nursing pharmacology
Antirejection immunosuppressants: Nursing pharmacology
Corticosteroids - Inhaled: Nursing pharmacology
Acetylcholinesterase inhibitors for myasthenia gravis: Nursing pharmacology
Mast cell stabilizers - Inhaled: Nursing pharmacology
Analgesics: Nursing pharmacology
Leukotriene modifiers: Nursing pharmacology
Antiepileptics: Nursing pharmacology
Medications for Alzheimer disease: Nursing pharmacology
Medications to control airway secretions: Nursing pharmacology
Skeletal muscle relaxants: Nursing pharmacology
Oxygen therapy: Nursing pharmacology
Medications for migraines: Nursing pharmacology
Plant extracts for chemotherapy: Nursing pharmacology
Antitumor antibiotics: Nursing pharmacology
Alkylating agents: Nursing pharmacology
Hormones and hormone modulators for cancer: Nursing pharmacology
Other antineoplastics: Nursing pharmacology
Antimetabolites: Nursing pharmacology
Platinum-based agents: Nursing pharmacology

Notes

MEDICATIONS TO TREAT ALZHEIMER DISEASE
DRUG NAME
rivastigmine (Exelon), galantamine (Razantine), donepezil (Aricept)
memantine (Namenda)
CLASS
Acetylcholinesterase inhibitors
NMDA receptor antagonist
MECHANISM OF ACTION
Inhibit acetylcholinesterase, resulting in a buildup of acetylcholine in the synaptic cleft
Prevents glutamate from binding to NMDA receptors, causing excessive calcium influx and neuronal damage
INDICATIONS
Alzheimer disease
ROUTE(S) OF ADMINISTRATION
  • PO
  • Transdermal patch
  • PO
SIDE EFFECTS
  • Miosis, blurred vision
  • Headache, dizziness, drowsiness
  • Dyspnea, persistent cough
  • Bradycardia, heart block, hypotension, cardiac arrest
  • Nausea, vomiting, diarrhea, involuntary defecation, gastrointestinal bleeding
  • Weakness, weight loss
  • Urgency to urinate
  • Headache, agitation, drowsiness
  • Nausea, vomiting, diarrhea, constipation
CONTRAINDICATIONS AND CAUTIONS
  • Intestinal or urinary obstruction
  • Pregnancy and breastfeeding
  • Peptic ulcer disease
  • Arrhythmias, coronary artery disease
  • Asthma, COPD
  • Epilepsy or a history of seizures
  • Severe hepatic or renal impairment
  • Pregnancy and breastfeeding
  • Epilepsy or a history of seizures
  • Severe hepatic or renal impairment
NURSING CONSIDERATIONS: MEDICATIONS TO TREAT ALZHEIMER DISEASE
DRUG NAME
rivastigmine (Exelon), galantamine (Razantine), donepezil (Aricept)
memantine (Namenda)
ASSESSMENT AND MONITORING
Baseline assessment
  • Weight
  • Vital signs
  • Hepatic and renal function
  • Cardiac and respiratory function
  • Cognitive and behavioral function
CLIENT EDUCATION
  • Make position changes slowly; caution during ambulation
  • Take medication with food to decrease gastric upset
  • Report symptoms such as cough or trouble breathing, diarrhea, urinary urgency
  • Take medication with or without food
  • Measure liquid form using provided dispenser
  • Store at room temperature in a dry place
  • Maintain a balanced diet to to promote balanced urine pH
Author: Antonia Syrnioti, MD
Author: Kimberly Clay BSN, RN
Illustrator: Robyn Hughes, MScBMC

Transcript

Watch video only

Alzheimer disease is the most common cause of dementia, and although there’s no cure, certain medications can be used to help mitigate some of the symptoms and improve the client’s quality of life.

Now, these medications can be broadly divided into two classes; acetylcholinesterase inhibitors and NMDA receptor antagonists.

Starting with acetylcholinesterase inhibitors, these include rivastigmine, galantamine, and donepezil. Acetylcholinesterase inhibitors are taken orally, while rivastigmine can be taken in the form of a transdermal patch as well as orally.

Once absorbed into the bloodstream, they travel to the brain. Here, they inhibit the enzyme acetylcholinesterase, which normally breaks down the neurotransmitter acetylcholine.

As a result, acetylcholine builds up in the synaptic cleft, causing increased and prolonged effects. And since there's some evidence suggesting that Alzheimer disease is related to low levels of acetylcholine in the brain, acetylcholinesterase inhibitors can help improve symptoms.

However, increased acetylcholine levels can also cause cholinergic side effects like miosis, blurred vision, headaches, dizziness, and drowsiness.

At the same time, in the airways, acetylcholine triggers bronchoconstriction and increases bronchial secretions, which can manifest with dyspnea and a persistent cough.

In the cardiovascular system, acetylcholine slows down the heart rate and reduces blood pressure, which can result in bradycardia, heart block, hypotension, and even cardiac arrest.

In the gastrointestinal tract, these medications can cause increased motility and secretions, leading to nausea, vomiting, cramps, diarrhea, increased salivation, and involuntary defecation, or even gastrointestinal bleeding.

Finally, in the urinary tract, acetylcholine stimulates the bladder muscles and sphincter relaxation, which may cause a sense of urgency.

As far as contraindications go, acetylcholinesterase inhibitors should be used with caution in clients with bradycardia, as well as those with intestinal or urinary obstruction.

Acetylcholinesterase inhibitors should also be used with caution during pregnancy or while breastfeeding, as well as in clients with epilepsy or a history of seizures, as well as asthma, chronic obstructive pulmonary disease, arrhythmias, coronary artery disease, as well as peptic ulcer disease, and severe hepatic or renal impairment.

Next, there are NMDA receptor antagonists, the most common of which is memantine, which is taken orally. As their name implies, NMDA receptor antagonists work by blocking N-methyl-D-aspartate or NMDA receptors in the brain.

In Alzheimer disease, there’s too much of a neurotransmitter called glutamate, which binds to NMDA receptors and allows an excessive influx of calcium, ultimately causing neuronal damage and cellular death. So, NMDA receptor antagonists can limit the calcium influx and prevent neuronal damage.

Now, side effects commonly associated with NMDA receptor antagonists include drowsiness, headache, and agitation. Other side effects include nausea, vomiting, and either constipation or diarrhea.

Finally, NMDA receptor antagonists should be used with caution in pregnant or breastfeeding clients, as well as those with epilepsy or a history of seizures and severe hepatic or renal impairment.

Sources

  1. "Karch’s Focus on Nursing Pharmacology, 9th edition" LWW (2023)
  2. "Pharmacology: A Patient-Centered Nursing Process Approach, 9th edition" Elsevier Canada (2020)
  3. "Mosby’s 2023 Nursing Drug Reference, 36th edition" Mosby (2022)
  4. "Saunders Comprehensive Review for the NCLEX-RN, 9th Edition" Saunders (2022)
  5. "Comprehensive Review on Alzheimer's Disease: Causes and Treatment" Molecules (2020)
  6. "The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management" Med Clin North Am (2019)